Traditional Chinese medicines and Alzheimer's disease

Taiwanese Journal of Obstetrics and Gynecology

Volumn 50, Issue 2, 2011, Pages 131-135

  Wu, Tzong Yuan ^a   Chen, Chip Ping ^b,c,d,e   Jinn, Tzyy Rong ^d  

^a CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Cognitive impairment; Dementia; Neuroprotection; Traditional Chinese medicine

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CARINATUMINE A; CARINATUMINE B; CHOLINESTERASE INHIBITOR; CORYNOXEINE; GALANTAMINE; GEISSOSCHIZINE METHYL ETHER; GINKGO BILOBA EXTRACT; HIRSUTEINE; HIRSUTINE; HUPERZINE A; HUPERZINE B; ISOCORYNOXEINE; ISORHYNCHOPHYLLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C JUN; RHYNCHOPHYLLINE; ROSMARINIC ACID; SALVIA OFFICINALIS EXTRACT; TENUIFOLIN; UNCARIA RHYNCHOPHYLLA EXTRACT; UNCLASSIFIED DRUG; URSOLIC ACID;

ALZHEIMER DISEASE; AMARYLLIDACEAE; AMNESIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; CHINESE MEDICINE; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; CHOLINESTERASE INHIBITION; COGNITION; DISEASE COURSE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG MECHANISM; ENZYME ACTIVITY; GALANTHUS WORONOWII; GINKGO BILOBA; HEADACHE; HIGHER PLANT; HUMAN; HUPERZIA; HUPERZIA SERRATA; INTERNAL RIBOSOME ENTRY SITE; LIPID PEROXIDATION; LYCORIS ARUEA; LYCORIS RADIATE; LYCORIS SQUAMIGERIC; MEDICINAL PLANT; MEMORY; MICROGLIA; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PLANT LEAF; PLANT ROOT; POLYGALA TENUIFOLIA; PROTEIN EXPRESSION; REVIEW; SALVIA OFFICINALIS; SENILE DEMENTIA; SENILE PLAQUE; SIGNAL TRANSDUCTION; SYNAPSE; THROMBOCYTE AGGREGATION INHIBITION; TINNITUS; UNCARIA; UNCARIA RHYNCHOPHYLLA; UNSPECIFIED SIDE EFFECT; VERTIGO;

ALZHEIMER DISEASE; DRUGS, CHINESE HERBAL; GINKGO BILOBA; HUMANS; HUPERZIA; LILIACEAE; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY; POLYGALA; SALVIA OFFICINALIS; UNCARIA;

EID: 79960633914     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2011.04.004     Document Type: Review

References (53)

1. Wancata J., Musalek M., Alexandrowicz R., Krautgartner M. Number of dementia suffers in Europe between the years 2000 and 2050. Eur Psychiatry 2003, 18:306-313.
2. Fantini J., Yahi N. Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. Expert Rev Mol Med 2010, 12:27.
3. Lin H.Q., Ho M.T., Lau L.S., Wong K.K., Shaw P.C., Wan C.C. Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease. Chem Biol Interact 2008, 175:352-354.
4. Shoji M. Drug therapy for Alzheimer's disease. Brain Nerve 2010, 62:777-785.
5. Ma X., Tan C., Zhu D., Gang D.R., Xiao P. Huperzine A from Huperzia species-an ethnopharmacological review. J Ethnopharmacol 2007, 113:15-34.
6. Wang R., Yan H., Tang X.C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006, 27:1-26.
7. Zhang H.Y., Tang X.C. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 2006, 27:619-625.
8. Wang R., Tang X.C. Neuroprotective effects of huperzine A: a natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals 2005, 14:71-78.
9. Hualiang J., Xiaomin L., Donglu B. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional Chinese medicine origin for the treatment of Alzheimer's disease. Curr Med Chem 2003, 10:2231-2252.
10. Gao X., Tang X.C. Huperzine A attenuates mitochondrial dysfunction in beta-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism. J Neurosci Res 2006, 83:1048-1057.
11. Zhang H.Y., Yan H., Tang X.C. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004, 360:21-24.
12. Yang C.Y., Lv Z.P., Zheng C.G. Efficacy and reliability of huperzine A in mild and moderate Alzheimer's disease. Chin J Clin Rehabil 2003, 7:4258-4259.
13. Tang L.L., Wang R., Tang X.C. Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells. Acta Pharmacol Sin 2005, 26:673-678.
14. Wang Z.F., Tang L.L., Yan H., Wang Y.J., Tang X.C. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 2006, 83:603-611.
15. Tang X.C., Jin G.Z., Xu B. Neuropharmacologic actions of lycoramine and galanthamine. Acta Pharm Sin 1963, 10:465-473.
16. Wang Y., Huang L., Tang X., Zhang H. Retrospect and prospect of active principle from Chinese herbs in the treatment of dementia. Acta Pharm Sin 2010, 31:649-664.
17. Barnes C.A., Meltzer J., Houston F., Orr G., McGann K., Wenk G.L. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000, 99:17-23.
18. Belluardo N., Mudo G., Blum M., Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 2000, 113:21-34.
19. Shimohama S., Greenwald D.L., Shafron D.H., Akaika A., Maeda T., Kaneko S., et al. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 1998, 779:359-363.
20. Giunta B., Ehrhart J., Townsend K., Sun N., Vendrame M., Shytle D., et al. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull 2004, 64:165-170.
21. Repantis D., Laisney O., Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010, 61:473-481.
22. Ezoulin M.J., Ombetta J.E., Dutertre-Catella H., Warnet J.M., Massicot F. Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. Neurotoxicology 2008, 29:270-277.
23. Cao X.Z., Zhang L.M., Shen Y.E., Zhou S.S., Jiang G.H. NMDA receptors mediate the effect of galantamin on the cognitive function of Alzheimer's disease in rats. J Apop Nerv Dis 2006, 23:678-680.
24. Mulder J., Harkany T., Czollner K., Cremers T.I., Keijser J.N., Nyakas C., et al. Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum. Behav Brain Res 2005, 163:33-41.
25. Moriguchi S., Marszalec W., Zhao X., Yeh J.Z., Narahashi T. Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 2004, 310:933-942.
26. Melo J.B., Sousa C., Garcao P., Oliveira C.R., Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci 2009, 29:455-464.
27. Matharu B., Gibson G., Parsons R., Huckerby T.N., Moore S.A., Cooper L.J., et al. Galantamine inhibits beta-amyloid aggregation and cytotoxicity. J Neurol Sci 2009, 280:49-58.
28. Arias E., Ales E., Gabilan N.H., Cano-Abad M.F., Villarroya M., Garcia A.G., et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004, 46:103-114.
29. Gertz H.J., Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des 2004, 10:261-264.
30. Weinmann S., Roll S., Schwarzbach C., Vauth C., Willich S.N. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2010, 10:1-14.
31. Lu G., Wu Y., Mak Y.T., Wai S.M., Feng Z.T., Rudd J.A., et al. Molecular evidence of the neuroprotective effect of Ginkgo biloba (EGb761) using bax/bcl-2 ratio after brain ischemia in senescence-accelerated mice, strain prone-8. Brain Res 2006, 1090:23-28.
32. Calapai G., Crupi A., Firenzuoli F., Marciano M.C., Squadrito F., Inferrera G., et al. Neuroprotective effects of Ginkgo biloba extract in brain ischemia are mediated by inhibition of nitric oxide synthesis. Life Sci 2000, 67:2673-2683.
33. Eckert A., Kreil U., Kressmann S., Schindowski K., Leutner S., Lutz S., et al. Effects of Egb761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry 2003, 36:15-23.
34. Li F.M., Duan X.M., Wang J.J., Fang H.L. Effects of Ginkgo biloba extract on MitoKATP in focal cerebral ischemia-reperfusion rats. Chin Arch Tradit Chin Med 2008, 26:1462-1463.
35. Kasper S., Schubert H. Ginkgo biloba extract EGb 761(R) in the treatment of dementia: evidence of efficacy and tolerability. Fortschr Neurol Psychiatr 2009, 77:494-506.
36. Wang S.Y., Liu X.M., Wang J.X., Liu Y.X., Yuang D.X. Effect of EGb on GFAP in focal cerebral ischemia-reperfusion injury rats. Anatomy Res 2008, 30:115-117. [in Chinese].
37. Kang T.H., Murakami Y., Takayama H., Kitajima M., Aimi N., Watanabe H., et al. Protective effect of rhynchophylline and isorhynchophylline on in vitro ischemia-induced neuronal damage in the hippocampus: putative neurotransmitter receptors involved in their action. Life Sci 2004, 76:331-343.
38. Wirths O., Malthaup G., Bayer T.A. A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide-the first step of a fatal cascade. J Neurochem 2004, 91:513-520.
39. Fujiwara H., Iwasaki K., Furukawa K., Seki T., He M., Maruyama M., et al. Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer's beta-amyloid proteins. J Neurosci Res 2006, 84:427-433.
40. Chung I.W., Moore N.A., Oh W.K., O'Neill M.F., Ahn J.S., Park J.B., et al. Behavioural pharmacology of polygalasaponins indicates potential antipsychotic efficacy. Pharmacol Biochem Behav 2002, 71:191-195.
41. Kim H.M., Lee E.H., Lee H.J., Shin S.B., Lyu T.Y., Kim Y.S., et al. Effect of Polygala tenuifolia root extract on the tumor necrosis factor-alpha secretion from mouse astrocytes. J Ethnopharmacol 1998, l61:201-208.
42. Lv J., Jia H., Jiang Y., Ruan Y., Liu Z., Yue W., et al. Tenuifolin, an extract derived from tenuigenin, inhibits amyloid-β secretion in vitro. Acta Physiol 2009, 196:419-425.
43. Jia H., Jiang Y., Ruan Y., Zhang Y., Ma X., Zhang J., et al. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. Neurosci Lett 2004, 367:123-128.
44. Schwarz K., Ternes W. Antioxidative constitutents of Rosmarinus officinalis and Salvia officinalis. II. Isolation of carnosic acid and formation of other phenolic diterpenes. Z Lebensm Unters Forsch 1992, 195:99-103.
45. Lu J., Zheng Y.L., Wu D.M., Luo L., Sun D.X., Shan Q. Ursolic acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. Biochem Pharmacol 2007, 74:1078-1090.
46. Sofic E., Sapcanin A., Tahirovic I., Gavrankapetanovic I., Jellinger K., Reynolds G.P., et al. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. J Neural Transm Suppl 2006, 71:39-43.
47. Akhondzadeh S., Noroozian M., Mohammadi M., Ohadinia S., Jamshidi A.H., Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003, 28:53-59.
48. Chung Y.K., Heo H.J., Kim E.K., Kim H.K., Huh T.L., Lim Y. Inhibitory effect of ursolic acid purified from Origanum majorana L on the acetylcholinesterase. Mol Cells 2001, 11:137-143.
49. Porat Y., Abramowitz A., Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006, 67:23-37.
50. Ono K., Hasegawa K., Naiki H., Yamada M. Curcumin has potent antiamyloiaogenic effects for Alzhemer's beta-amyloid fibrils in vitro. J Neurosci Res 2004, 75:742-750.
51. Chen Y.J., Zeng S.J., Hsu J.T., Horng J.T., Yang H.M., Shih S.R., et al. Amantadine as a regulator of internal ribosome entry site. Acta Pharmacol Sin 2008, 29:1327-1333.
52. Wu T.Y., Chen C.P. Dual action of memantine in Alzheimer disease: a hypothesis. Taiwan J Obstet Gynecol 2009, 48:273-277.
53. Wu T.Y., Chen C.P., Jinn T.R. Alzheimer's disease: aging, insomnia and epigenetics. Taiwan J Obstet Gynecol 2010, 49:468-472.